Page 40 - Amgen News Today

Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease. The Phase IIa COURSE trial was a...

High drug prices in the US are a serious problem for both patients and the health care system. Prices of branded drugs are driven higher by monopoly

News from Texas A&M University

Sanofi and Regeneron provided trial results which bolster their pursuit of an FDA approval to treat chronic obstructive pulmonary disease.

Driving Long-Term Growth: IMDELLTRA Approval and Inflammation Update May 20, 2024 ...

Sachetta LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,998 shares of the medical research company’s stock, valued at approximately $576,000. Several other institutional investors and hedge funds have also made […]

SAN DIEGO, May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) announced today that Anna Richo has joined the companys Board of Directors fo

The United States Patent and Trademark Office (USPTO, the Office or the Agency) has recently issued multiple guidance and proposed rules that potentially change the landscape of patent practice.

Millions of people are injecting themselves with weight loss drugs, either officially, after seeking medical advice, or unofficially, after seeing celebrities wax lyrical about their effects.

Eli Lilly's biggest growth drivers today are its weight loss drugs.